Orencia (abatacept) becomes the first drug to be approved to prevent GvHD, a condition in which donor immune cells attack tissues in the patient receiving an HSCT, commonly known as a bone marrow ...

Biologic response modifier Common adverse effects Rare/serious toxicities Abatacept (Orencia®) Infusion ... use of disease-modifying antirheumatic drugs (DMARDs) is indicated for patients with ...

The initiation of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), particularly rituximab and abatacept, is associated with an increased risk for incident cancer ...